首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1534259

全球出血性疾病治療市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Bleeding Disorder Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 131 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球出血性疾病治療市場需求預計將從 2023 年的 162.9 億美元達到 2032 年近 343.9 億美元的市場規模，2024-2032 年研究期間複合年成長率為 8.66%。

出血性疾病治療包括一系列治療介入措施，旨在控制以凝血受損或異常出血傾向為特徵的病症。這些疾病，例如血友病、馮維勒布蘭德病和血小板功能障礙，是由凝血因子、血小板或血管完整性的缺乏或缺陷引起的。治療策略依具體疾病而有所不同，可能包括凝血因子替代療法、抗纖維蛋白溶解劑、去氨加壓素，在某些情況下還包括基因療法。這些治療旨在控制出血事件，預防關節損傷或器官出血等併發症，並提高受影響個體的整體生活品質。治療方式的進步顯著改善了結果，允許考慮疾病嚴重程度、患者年齡和生活方式因素的個人化方法。

市場動態

由於遺傳易感性、人口老化和疾病意識提高等因素，全球出血性疾病的盛行率不斷增加，有助於出血性疾病治療市場的擴張。此外，治療方案的進步，包括延長半衰期的凝血因子和基因編輯和 RNA 干擾等新型療法，正在透過提供更有效、更方便的治療方案來改變患者的照護。不斷成長的醫療保健支出，尤其是在已開發經濟體，支持了對創新療法研發的投資。這些努力旨在提高治療效果、減輕治療負擔、提高患者依從性。此外，透過合作夥伴關係和政府措施改善發展中地區獲得治療的機會正在擴大市場範圍。此外，不斷變化的監管環境簡化了新療法的核准流程並為罕見疾病治療提供了激勵，進一步刺激了市場成長。製藥公司和研究機構之間的策略合作也推動創新並加速下一代出血性疾病療法的開發。然而，某些地區高昂的治療成本和有限的專業護理機會是市場成長的重大障礙。經濟限制和昂貴療法的報銷挑戰阻礙了採用率，特別是在發展中國家，從而限制了出血性疾病治療市場的擴張。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球出血性疾病治療市場的各個細分市場進行了包容性評估。出血性疾病治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

出血性疾病治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按類型分析

甲型血友病
乙型血友病
血管性血友病
其他

按藥物類別

血漿衍生凝血因子濃縮物
重組凝血因子濃縮物
去氨加壓素
抗纖溶藥
纖維蛋白密封劑
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲出血性疾病治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。出血性疾病治療市場的主要參與者包括拜耳公司、CSL Behring、諾和諾德、輝瑞公司、Shire PLC、Grifols SA、Octapharma、安進公司、Cangene Corporation、Alnylam Pharmaceuticals。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：出血性疾病治療公司的競爭格局

出血性疾病治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Bayer AG

公司概況
公司收入
產品
最新動態

CSL Behring

公司概況
公司收入
產品
最新動態

Novo Nordisk

公司概況
公司收入
產品
最新動態

Pfizer Inc.

公司概況
公司收入
產品
最新動態

Shire PLC

公司概況
公司收入
產品
最新動態

Grifols SA

公司概況
公司收入
產品
最新動態

Octapharma

公司概況
公司收入
產品
最新動態

Amgen Inc.

公司概況
公司收入
產品
最新動態

Cangene Corporation

公司概況
公司收入
產品
最新動態

Alnylam Pharmaceuticals

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112115274

The global demand for Bleeding Disorder Treatment Market is presumed to reach the market size of nearly USD 34.39 Billion by 2032 from USD 16.29 Billion in 2023 with a CAGR of 8.66% under the study period 2024-2032.

Bleeding disorder treatments encompass a range of therapeutic interventions aimed at managing conditions characterized by impaired blood clotting or abnormal bleeding tendencies. These disorders, such as hemophilia, von Willebrand disease, and platelet function disorders, result from deficiencies or defects in clotting factors, platelets, or blood vessel integrity. Treatment strategies vary based on the specific disorder and may include clotting factor replacement therapies, antifibrinolytics, desmopressin, and, in some cases, gene therapy. These treatments aim to control bleeding episodes, prevent complications like joint damage or organ bleeding, and improve the overall quality of life for affected individuals. Advances in treatment modalities have significantly enhanced outcomes, allowing for personalized approaches that consider disease severity, patient age, and lifestyle factors.

MARKET DYNAMICS

The increasing prevalence of bleeding disorders globally due to factors such as genetic predisposition, aging population, and improved disease awareness contribute to bleeding disorder treatments market expansion. Moreover, advancements in treatment options, including extended half-life clotting factors and novel therapies like gene editing and RNA interference, are transforming patient care by offering more effective and convenient treatment regimens. Rising healthcare expenditure, especially in developed economies, supports investment in research and development of innovative therapies. These efforts aim to improve treatment efficacy, reduce treatment burden, and enhance patient compliance. Additionally, initiatives to improve access to treatment in developing regions through partnerships and government initiatives are expanding market reach. Furthermore, evolving regulatory landscapes that streamline approval processes for new therapies and provide incentives for rare disease treatments further stimulate market growth. Strategic collaborations between pharmaceutical companies & research institutions also drive innovation & accelerate the development of next-generation therapies for bleeding disorders. However, high treatment costs and limited access to specialized care in certain regions are significant barriers to market growth. Economic constraints and reimbursement challenges for expensive therapies hinder adoption rates, particularly in developing countries, thereby restricting the expansion of the bleeding disorder treatment market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Bleeding Disorder Treatment. The growth and trends of Bleeding Disorder Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Bleeding Disorder Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type Analysis

Hemophilia A
Hemophilia B
Von Willebrand Disease
Others

By Drug Class

Plasma-Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Desmopressin
Antifibrinolytic
Fibrin Sealants
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Bleeding Disorder Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Bleeding Disorder Treatment market include Bayer AG, CSL Behring, Novo Nordisk, Pfizer Inc., Shire PLC, Grifols SA, Octapharma, Amgen Inc., Cangene Corporation, Alnylam Pharmaceuticals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. BLEEDING DISORDER TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type Analysis
- 3.7.2 Market Attractiveness Analysis By Drug Class
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL BLEEDING DISORDER TREATMENT MARKET ANALYSIS BY TYPE ANALYSIS

5.1. Overview By Type Analysis
5.2. Historical and Forecast Data Analysis By Type Analysis
5.3. Hemophilia A Historic and Forecast Sales By Regions
5.4. Hemophilia B Historic and Forecast Sales By Regions
5.5. Von Willebrand Disease Historic and Forecast Sales By Regions
5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL BLEEDING DISORDER TREATMENT MARKET ANALYSIS BY DRUG CLASS

6.1. Overview By Drug Class
6.2. Historical and Forecast Data Analysis By Drug Class
6.3. Plasma-Derived Coagulation Factor Concentrates Historic and Forecast Sales By Regions
6.4. Recombinant Coagulation Factor Concentrates Historic and Forecast Sales By Regions
6.5. Desmopressin Historic and Forecast Sales By Regions
6.6. Antifibrinolytic Historic and Forecast Sales By Regions
6.7. Fibrin Sealants Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL BLEEDING DISORDER TREATMENT MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE BLEEDING DISORDER TREATMENT COMPANIES

8.1. Bleeding Disorder Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF BLEEDING DISORDER TREATMENT INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Bayer AG
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. CSL Behring
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Novo Nordisk
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Pfizer Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Shire PLC
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Grifols SA
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Octapharma
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Amgen Inc.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Cangene Corporation
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Alnylam Pharmaceuticals
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

簡介目錄圖表

LIST OF TABLES

Market Snapshot
Drivers: Impact Analysis
Restraints: Impact Analysis
List of Raw Material
List of Raw Material Manufactures
Analysis By Type Analysis (USD MN)
Hemophilia A Market Sales By Geography (USD MN)
Hemophilia B Market Sales By Geography (USD MN)
Von Willebrand Disease Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Analysis By Drug Class (USD MN)
Plasma-Derived Coagulation Factor Concentrates Market Sales By Geography (USD MN)
Recombinant Coagulation Factor Concentrates Market Sales By Geography (USD MN)
Desmopressin Market Sales By Geography (USD MN)
Antifibrinolytic Market Sales By Geography (USD MN)
Fibrin Sealants Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Bleeding Disorder Treatment Market Sales By Geography (USD MN)
North America Market Analysis (USD MN)
United States Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate By Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Bleeding Disorder Treatment Report
Market Research Process
Market Research Methodology
Global Bleeding Disorder Treatment Market Size, By Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis By Type Analysis
Market Attractiveness Analysis By Drug Class
Market Attractiveness Analysis By Region
Value Chain Analysis
Global Market Analysis By Type Analysis (USD MN)
Hemophilia A Market Sales By Geography (USD MN)
Hemophilia B Market Sales By Geography (USD MN)
Von Willebrand Disease Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Analysis By Drug Class (USD MN)
Plasma-Derived Coagulation Factor Concentrates Market Sales By Geography (USD MN)
Recombinant Coagulation Factor Concentrates Market Sales By Geography (USD MN)
Desmopressin Market Sales By Geography (USD MN)
Antifibrinolytic Market Sales By Geography (USD MN)
Fibrin Sealants Market Sales By Geography (USD MN)
Others Market Sales By Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis